Telix Pharmaceuticals Limited (MUN:T3X) Filings

Telix Pharmaceuticals Limited

Filings

FilingDateTypeFiled with
Appendix 3Y Maria RivasNov 4, 2026Other filingsASX
Telix Capital Markets Day Presentation November 2026Nov 3, 2026Other filingsASX
Change of Director's Interest Notice - Marie McDonaldNov 3, 2026Ownership change noticeASX
Notification regarding unquoted securities - TLXNov 3, 2026Other filingsASX
Cancellation of Appendix 2ANov 2, 2026FinancingASX
Telix Notice of General Meeting, Proxy Form and Online GuideOct 29, 2026Meeting noticeASX
6-K · Report of a foreign issuerOct 29, 2026Current reportSEC
Application for quotation of securities - TLXOct 28, 2026FinancingASX
Appendix 3Y Dr Christian BehrenbruchOct 26, 2026Other filingsASX
Appendix 3Y William JellisonOct 25, 2026Other filingsASX
Appendix 3Y Change in Director Interest - D GillOct 25, 2026Management or board changeASX
6-K · Report of a foreign issuerOct 20, 2026Current reportSEC
Telix Reports Third Quarter 2026 Financial PerformanceOct 20, 2026Quarterly reportASX
Telix Reports Third Quarter 2026 Financial PerformanceOct 20, 2026Quarterly reportASX
Notification of cessation of securities - TLXOct 4, 2026FinancingASX
Notification regarding unquoted securities - TLXOct 4, 2026Other filingsASX
Application for quotation of securities - TLXOct 4, 2026FinancingASX
6-K · Report of a foreign issuerSep 29, 2026Current reportSEC
FDA Fast Track for BiPASS Pre Biopsy Prostate ImagingSep 29, 2026Operations updateASX
Change in substantial holdingSep 25, 2026Ownership change noticeASX
Appendix 3Y Change in Director Interest-D GillSep 25, 2026Management or board changeASX
Application for quotation of securities - TLXSep 25, 2026FinancingASX
Grant of waivers of Listing Rule 7.3.4Sep 21, 2026Acquisition or disposalASX
6-K · Report of a foreign issuerSep 21, 2026Current reportSEC
Telix and ITM Join Forces to Create Radiopharma PowerhouseSep 20, 2026Other filingsASX
Telix and ITM Join Forces to Create Radiopharma PowerhouseSep 20, 2026Acquisition or disposalASX
4 · Change in ownershipSep 14, 2026Insider tradeSEC
6-K · Report of a foreign issuerSep 14, 2026Current reportSEC
Application for quotation of securities - TLXSep 14, 2026FinancingASX
FDA Approves Telix Brain Cancer Imaging Drug PixclaraSep 13, 2026Operations updateASX
6-K · Report of a foreign issuerSep 1, 2026Current reportSEC
Telix Completes Enrollment in Phase 3 BiPASS StudySep 1, 2026Operations updateASX
6-K · Report of a foreign issuerAug 31, 2026Current reportSEC
6-K · Report of a foreign issuerAug 19, 2026Current reportSEC
Telix HY26 Results PresentationAug 19, 2026Other filingsASX
Telix HY26 Results AnnouncementAug 19, 2026ResultsASX
Telix HY26 Appendix 4D and Interim ReportAug 19, 2026Interim reportASX
Telix H1 2026 Results - Investor Webcast NotificationJul 30, 2026Other filingsASX
6-K · Report of a foreign issuerJul 21, 2026Current reportSEC
Q2 2026 Revenue US$247M Strong Momentum Pipeline ProgressJul 20, 2026ResultsASX
6-K · Report of a foreign issuerJul 2, 2026Current reportSEC
FDA Alignment to Advance ProstACT Global Phase 3 TrialJul 1, 2026Other filingsASX
6-K · Report of a foreign issuerMay 21, 2026Current reportSEC
3 · Initial statement of ownershipMay 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
UPLOAD · Letter from the SECApr 23, 2026Other filingsSEC
6-K · Report of a foreign issuerApr 22, 2026Current reportSEC
6-K · Report of a foreign issuerApr 21, 2026Current reportSEC
6-K · Report of a foreign issuerApr 20, 2026Current reportSEC
CORRESP · Letter to the SECApr 17, 2026Other filingsSEC
Telix Successfully Prices Upsized US$600M Convertible BondsApr 14, 2026FinancingASX
6-K · Report of a foreign issuerApr 14, 2026Current reportSEC
Telix Investor Presentation April 2026Apr 14, 2026Other filingsASX
Telix Refinances Convertible BondsApr 14, 2026FinancingASX
6-K · Report of a foreign issuerApr 14, 2026Current reportSEC
6-K · Report of a foreign issuerApr 13, 2026Current reportSEC
Telix and Regeneron Announce Radiopharma CollaborationApr 12, 2026Operations updateASX
FDA Accepts NDA for TLX101-Px (Pixclara)Apr 9, 2026Operations updateASX
6-K · Report of a foreign issuerApr 9, 2026Current reportSEC
6-K · Report of a foreign issuerApr 8, 2026Current reportSEC
6-K · Report of a foreign issuerApr 7, 2026Current reportSEC
Q1 2026 Strong Revenue Growth and Tx Pipeline AdvancementApr 6, 2026ResultsASX
UPLOAD · Letter from the SECApr 3, 2026Other filingsSEC
6-K · Report of a foreign issuerApr 2, 2026Current reportSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
20-F/A · Annual report, amendedMar 20, 2026Annual reportSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
6-K · Report of a foreign issuerMar 16, 2026Current reportSEC
Telix Resubmits NDA to FDA for Pixclara Brain Cancer ImagingMar 15, 2026Operations updateASX
6-K · Report of a foreign issuerMar 10, 2026Current reportSEC
ProstACT Global Phase 3 (Part 1) Results PresentationMar 9, 2026Other filingsASX
ProstACT Global Phase 3 (Part 1) Achieves Primary ObjectivesMar 9, 2026Other filingsASX
F-3ASRFeb 20, 2026Other filingsSEC
2025 Full Year Results PresentationFeb 19, 2026ResultsASX
Appendix 4E and 2025 Annual ReportFeb 19, 2026Annual reportASX
2025 Full Year Results AnnouncementFeb 19, 2026ResultsASX
20-F · Annual reportFeb 19, 2026Annual reportSEC
6-K · Report of a foreign issuerFeb 19, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 18, 2026Current reportSEC
Telix Submits EU MAA for TLX101-Px Brain Cancer ImagingFeb 17, 2026Operations updateASX
6-K · Report of a foreign issuerFeb 2, 2026Current reportSEC
6-K · Report of a foreign issuerJan 20, 2026Current reportSEC
Telix Achieves FY25 Guidance - US$804M, Q4 GrowthJan 20, 2026ResultsASX
Chinese NMPA Accepts New Drug Application for IlluccixJan 19, 2026Operations updateASX
6-K · Report of a foreign issuerJan 12, 2026Current reportSEC
6-K · Report of a foreign issuerDec 22, 2025Current reportSEC
Precision Medicine Portfolio UpdateDec 21, 2025Operations updateASX
6-K · Report of a foreign issuerDec 17, 2025Current reportSEC
ProstACT Global Study StatusDec 17, 2025Other filingsASX
6-K · Report of a foreign issuerDec 8, 2025Current reportSEC
1st Patient Dosed in ProstACT Global Randomized Tx ExpansionDec 7, 2025Operations updateASX
6-K · Report of a foreign issuerOct 14, 2025Current reportSEC
Telix Reports US$206M Revenue, FY 2025 Guidance UpgradedOct 14, 2025GuidanceASX
6-K · Report of a foreign issuerSep 23, 2025Current reportSEC
CMS Grants Transitional Pass-Through Status for GozellixSep 22, 2025Operations updateASX
Telix and FDA Agree Resubmission Pathway for Pixclara NDASep 8, 2025Other filingsASX
6-K · Report of a foreign issuerSep 8, 2025Current reportSEC
6-K · Report of a foreign issuerAug 28, 2025Current reportSEC
Telix Provides Regulatory Update on TLX250-CDxAug 27, 2025Legal or regulatory actionASX
Telix H1 2025 Results AnnouncementAug 20, 2025ResultsASX
Telix H1 2025 Results PresentationAug 20, 2025ResultsASX
Telix H1 2025 Appendix 4D and Interim ReportAug 20, 2025Interim reportASX
6-K · Report of a foreign issuerAug 20, 2025Current reportSEC
Historical Financials in USD and H12025 OPEX (Unaudited)Aug 4, 2025ResultsASX
6-K · Report of a foreign issuerJul 22, 2025Current reportSEC
Telix Reports US$204M Q2 Revenue, Up 63% YOYJul 22, 2025Other filingsASX
6-K · Report of a foreign issuerJul 9, 2025Current reportSEC
Gozellix Receives Permanent HCPCS CodeJul 9, 2025Operations updateASX
6-K · Report of a foreign issuerJun 11, 2025Current reportSEC
Telix Investor Day PresentationJun 11, 2025Other filingsASX
6-K · Report of a foreign issuerMay 21, 2025Current reportSEC
6-K · Report of a foreign issuerApr 28, 2025Current reportSEC
Telix Provides Regulatory Update on TLX101-CDxApr 27, 2025Legal or regulatory actionASX
6-K · Report of a foreign issuerApr 22, 2025Current reportSEC
Telix Reports US$186M Q1 Revenue, Up 62% YOYApr 22, 2025Other filingsASX
6-K · Report of a foreign issuerApr 17, 2025Current reportSEC
6-K · Report of a foreign issuerApr 17, 2025Current reportSEC
6-K · Report of a foreign issuerApr 7, 2025Current reportSEC
6-K · Report of a foreign issuerApr 3, 2025Current reportSEC
FDA Approves New Prostate Cancer Imaging Agent GozellixMar 20, 2025Operations updateASX
6-K · Report of a foreign issuerMar 20, 2025Current reportSEC
6-K · Report of a foreign issuerMar 18, 2025Current reportSEC
6-K · Report of a foreign issuerMar 12, 2025Current reportSEC
Telix Completes FAP-Targeting Theranostic AcquisitionMar 11, 2025Acquisition or disposalASX
6-K · Report of a foreign issuerFeb 26, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 26, 2025Current reportSEC
FDA accepts BLA and grants priority review for ZircaixFeb 25, 2025Other filingsASX
6-K · Report of a foreign issuerFeb 25, 2025Current reportSEC
Telix Announces Change in Reporting Currency to USDFeb 24, 2025Other filingsASX
6-K · Report of a foreign issuerFeb 24, 2025Current reportSEC
20-F · Annual reportFeb 24, 2025Annual reportSEC
6-K · Report of a foreign issuerFeb 21, 2025Current reportSEC
2024 Full Year Results PresentationFeb 20, 2025ResultsASX
2024 Full Year Results AnnouncementFeb 20, 2025ResultsASX
Appendix 4E and 2024 Annual ReportFeb 20, 2025Annual reportASX
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 13, 2025Current reportSEC
Illuccix Approved in the United KingdomFeb 12, 2025Operations updateASX
6-K · Report of a foreign issuerJan 31, 2025Current reportSEC
Telix Completes Acquisition of Tx Assets, Biologics PlatformJan 30, 2025Acquisition or disposalASX
Telix Completes Acquisition of RLS (USA) IncJan 27, 2025Acquisition or disposalASX
6-K · Report of a foreign issuerJan 27, 2025Current reportSEC
Illuccix Receives European ApprovalJan 16, 2025Operations updateASX
6-K · Report of a foreign issuerJan 16, 2025Current reportSEC
6-K · Report of a foreign issuerJan 13, 2025Current reportSEC
6-K · Report of a foreign issuerJan 13, 2025Current reportSEC
Telix JP Morgan Healthcare Conference 2025 PresentationJan 13, 2025Other filingsASX
Telix Exceeds FY24 Guidance with US$142M Q4 RevenueJan 13, 2025GuidanceASX
Presentation to Accompany Biologics Platform AcquisitionJan 12, 2025Acquisition or disposalASX
TLX to Acquire Next-Gen Therapeutics and Biologics PlatformJan 12, 2025Acquisition or disposalASX
6-K · Report of a foreign issuerDec 30, 2024Current reportSEC
S-8 · Registration statement for employee plansDec 19, 2024Offer documentSEC
SEC STAFF LETTERNov 21, 2024Other filingsSEC
6-K · Report of a foreign issuerNov 19, 2024Current reportSEC
Presentation to Accompany FAP-Targeting AcquisitionNov 18, 2024Acquisition or disposalASX
Telix Adds FAP-Targeting Theranostic Candidates to PipelineNov 18, 2024Other filingsASX
6-K · Report of a foreign issuerNov 14, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveNov 13, 2024Other filingsSEC
SEC STAFF ACTIONNov 12, 2024Other filingsSEC
CERT · Exchange's certificate of listingNov 12, 2024Other filingsSEC
CORRESP · Letter to the SECNov 12, 2024Other filingsSEC
CMS payment improvement decision for radiopharma diagnosticsNov 3, 2024Operations updateASX
SEC STAFF LETTEROct 30, 2024Other filingsSEC
20FR12B/AOct 29, 2024Other filingsSEC
FDA accepts NDA and grants priority review for PixclaraOct 23, 2024Operations updateASX
Telix Files Form 20-F Registration Statement for Nasdaq ADSOct 17, 2024Other filingsASX
F-6Oct 17, 2024Other filingsSEC
CORRESP · Letter to the SECOct 17, 2024Other filingsSEC
20FR12BOct 17, 2024Other filingsSEC
Telix Q3 2024 Revenue and Business UpdateOct 17, 2024ResultsASX
UPLOAD · Letter from the SECOct 10, 2024Other filingsSEC
Telix to Acquire RLS for US Manufacturing and DistributionSep 22, 2024Acquisition or disposalASX
DRS · Draft registration statementSep 13, 2024Offer documentSEC
Telix Submits NDA for TLX101-CDx Brain Cancer Imaging AgentAug 27, 2024Operations updateASX
Telix 1H 2024 Results ReleaseAug 22, 2024ResultsASX
Telix 1H 2024 Results PresentationAug 22, 2024Other filingsASX
Telix 1H 2024 Appendix 4D and Interim ReportAug 22, 2024Interim reportASX
Telix Completes A$650 Million of Convertible BondsJul 30, 2024FinancingASX
Convertible Bond Cleansing NoticeJul 29, 2024FinancingASX
Telix Successfully Prices A$650M Convertible BondsJul 23, 2024FinancingASX
Telix Announces A$600 Million Convertible Bonds OfferingJul 23, 2024FinancingASX
Telix Q2 2024 Revenue/Business Highlights, Guidance UpgradeJul 17, 2024ResultsASX
CMS proposes payment improvement for radiopharma diagnosticsJul 11, 2024Operations updateASX
RW · Request to withdraw a registrationJun 14, 2024Other filingsSEC
RW · Request to withdraw a registrationJun 14, 2024Other filingsSEC
Telix Elects to Withdraw from Proposed U.S. ListingJun 13, 2024Other filingsASX
Trading HaltJun 12, 2024Trading halt or suspensionASX
8-A12B · Registration of shares for listing on an exchangeJun 10, 2024Other filingsSEC
Telix Launches Proposed US IPOJun 5, 2024Offer documentASX
F-1/A · Registration statement, amendedJun 5, 2024Offer documentSEC
Telix Completes TLX250-CDx (Zircaix) BLA SubmissionJun 2, 2024Operations updateASX

This page holds 200 of 441 filings.

All of its filings on SEC EDGAR